Skip to main content
MedPathMedPath Home
Clinical Trials/NCT07460375
NCT07460375
Not yet recruiting
Phase 1

A First-in-Human Phase 1/2, Dose Escalation and Dose Expansion Study to Evaluate Safety, Tolerability, and Preliminary Efficacy of Claudin18.2 (CLDN18.2)-Directed Antibody-Drug Conjugate (ADC) LCB02A in Patients With CLDN18.2-positive Advanced Solid Tumors

LigaChem Biosciences, Inc.6 sites in 3 countries191 target enrollmentStarted: August 1, 2026Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
InterventionsLCB02A

Overview

Phase
Phase 1
Status
Not yet recruiting
Enrollment
191
Locations
6
Primary Endpoint
Safety of LCB02A (Phase 1 and 2)
OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Overview

Brief Summary

This is a Phase 1/2 open label study consisting of dose escalation cohorts (Phase 1) followed by expansion cohorts (Phase 2). The Phase 1 dose escalation population includes subjects with advanced solid tumors that are refractory to standard of care therapy or for whom no standard of care options are available. Once the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of single agent LCB02A is determined, the study will proceed to Phase 2 expansion cohorts in selected tumor types.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Phase 1 Dose Escalation: histologically or cytologically confirmed advanced solid tumors that are Claudin 18.2 positive and refractory to standard of care treatment.
  • •Phase 2 Dose Expansion: selected histologically or cytologically confirmed advanced solid tumors that are Claudin 18.2 positive and refractory to standard of care treatment. Expansion cohort indications will be prioritized based on data from the Phase 1 dose escalation portion.
  • •Prior treatment with Claudin 18.2 directed therapy is permitted.
  • •Measurable disease as defined by RECIST v1.1
  • •Willingness to provide archival tumor tissue when available, or to undergo a pre-treatment biopsy if archival tissue is not available.
  • •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
  • •Adequate organ function as defined by:
  • •Absolute neutrophil count ≥ 1.5 × 109/L , without colony stimulating factor support for the past 14 days
  • •Platelet count ≥ 100 × 109/L
  • •Hemoglobin level ≥ 9.0 g/dL

Exclusion Criteria

  • •Prior exposure to ADCs with a Topo1 inhibitor payload.
  • •Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
  • •Note: Patients may be considered for enrollment if they have previously treated brain metastases that are clinically stable or radiologically stable for at least 14 days prior to the first dose.
  • •Received radiotherapy within 21 days prior to the first dose of study drug. Note: For palliative radiotherapy for symptomatic improvement of non-central nervous system (CNS) lesions (total duration of radiotherapy ≤ 14 days), a radiation washout period of 7 days is required prior to the first dose.
  • •Any medical conditions that may confound the study results, interfere with the patient's compliance, or impair the interests of the subject, as assessed by the Investigator.

Arms & Interventions

LCB02A monotherapy

Experimental

Intervention: LCB02A (Drug)

Outcomes

Primary Outcomes

Safety of LCB02A (Phase 1 and 2)

Time Frame: Up to 48 months

Incidence and severity of AEs

Recommended Phase 2 dose of LCB02A (Phase 1)

Time Frame: Up to 24 months

Based on tolerability, preliminary anti-tumor activity, and pharmacokinetics

Objective response rate (Phase 2)

Time Frame: Up to 24 months

Assessed by RECIST 1.1

Secondary Outcomes

  • Duration of Response (Phase 1 and 2)(Up to 48 months)
  • Plasma concentrations of LCB02A (Phase 1 and 2)(Up to 48 months)
  • Disease control rate (Phase 1 and Phase 2)(Up to 48 months)
  • Progression Free Survival (Phase 1 and Phase 2)(Up to 48 months)
  • Overall Survival (Phase 1 and Phase 2)(Up to 48 months)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (6)

Loading locations...

Similar Trials

Recruiting
Phase 1
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
NCT07454642Avacta Life Sciences Ltd144
Recruiting
Phase 1
First in Human Multicenter Open Name Dose-increase,Consolidation method to Study Safety drug-level in Blood & drug metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients with, without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary glands tumor
CTRI/2024/07/070802Jubilant Therapeutics India Limited42
Recruiting
Phase 1
A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation.
NCT07456046D3 Bio (Wuxi) Co., Ltd42
Not yet recruiting
Phase 1
CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML or HR-MDS
NCT07347418University of Colorado, Denver23
Not yet recruiting
Phase 1/2
A first-in-human, dose escalation and dose expansion study of SAR445877 in adult participants with advanced solid tumors
2023-507141-28-00Sanofi-Aventis Recherche & Developpement115